Peco-Antić A, Popović-Rolović M, Jovanović O, Kostić M, Kruscić D
University Children's Hospital, Belgrade, Yugoslavia.
Srp Arh Celok Lek. 1992 May-Jun;120(5-6):147-52.
Nine pts, aged 4-20 years (mean 12) with chronic uremic anaemia (mean Hb 5.8 g/dl, range 5.0-7.0 g/dl) on regular thrice-weekly haemodialysis, were treated with human recombinant erythropoietin (rh-uEPO) for a mean of 28.11 weeks (range 4-48). To attain a target Hb concentration (9.6-11.2 g/dl) RH-uEPO (Cilag) was administered i.v. after each dialysis in increasing doses within the range (51-300 U/kg/week). All pts were treated with persantine. Five pts needed iron supplementation. All pts showed increased Hb concentration and none of 6 previously transfusion dependent pts needed further transfusions after the first week of rH-uEPO. Pretreatment long-term dialyzed, polytransfused and iron overloaded pts, even when treated with lower doses of rH-EPO, responded better, reaching target Hb level from the 8th- to the 16th week. Three of 4 highly sensitized pts on rH-EPO treatment had a significant decrease of cytotoxic antibody titre, and 2 were successfully transplanted. rH-EPO also significantly improved the life quality in all pts. No pts developed any serious side affects. There was a transient increase in BP (2 pts) and transaminase with eosinophilia (4 pts).
9例年龄在4至20岁（平均12岁）的慢性尿毒症贫血患者（平均血红蛋白5.8g/dl，范围5.0 - 7.0g/dl），每周规律进行3次血液透析，接受重组人促红细胞生成素（rh-uEPO）治疗，平均治疗28.11周（范围4 - 48周）。为达到目标血红蛋白浓度（9.6 - 11.2g/dl），每次透析后静脉注射rh-uEPO（Cilag），剂量在51 - 300U/kg/周范围内递增。所有患者均接受潘生丁治疗。5例患者需要补充铁剂。所有患者血红蛋白浓度均升高，6例先前依赖输血的患者在rh-uEPO治疗第一周后均无需进一步输血。长期接受透析、多次输血且铁过载的预处理患者，即使接受较低剂量的rH-EPO治疗，反应也更好，在第8至16周达到目标血红蛋白水平。4例接受rH-EPO治疗的高敏患者中有3例细胞毒性抗体滴度显著降低，2例成功进行了移植。rH-EPO还显著改善了所有患者的生活质量。无患者出现任何严重副作用。有2例患者血压短暂升高，4例患者转氨酶升高伴嗜酸性粒细胞增多。
